Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: del Barco, Diana García | Montero, Enrique | Coro-Antich, Rosa M. | Brown, Enma | Suarez-Alba, José | Lopez, Laura | Subirós, Nelvys | Berlanga, Jorge
Affiliations: Center for Genetic Engineering and Biotechnology, Cubanacan, Playa, Havana, Cuba | Center of Molecular Immunology, Atabey, Playa, Havana, Cuba | Institute of Neurology and Neurosurgery, Vedado, Havana, Cuba | Pathology Department of Institute of Nephrology , Havana, Cuba
Note: [] Corresponding author: Diana García del Barco MD, Pharmaceutical Division, Biomedical Research Direction, Center for Genetic Engineering and Biotechnology, Ave.31 e/158 & 190 P.O. Box 6162. Cubanacan, Playa 10600, Havana, Cuba. Tel.: +53 7 2716022; Fax: +53 7 273 1779; E-mail: [email protected]
Abstract: Purpose: Multiple sclerosis is a complex and devastating autoimmune disease of the central nervous system. Up to now, a constellation of candidate drugs have been evaluated with no major success. Experimental Autoimmune Encephalitis (EAE) is the animal counterpart that reproduces critical features of the human MS process. The aim of the present work is to study a possible therapeutic effect of epidermal growth factor (EGF) and growth hormone releasing peptide-6 (GHRP6 coadministration in mild and severe EAE. Methods: Mild and severe forms of EAE were generated immunizing rats and mice with xenogeneic spinal cord homogenate and with the encephalitogenic peptide MOGp35–35, respectively. EGF and GHRP6 alone or combined were administered in therapeutic and prophylactic schedules. A clinical score was established to follow-up the animals during the disease period. Malondialdehyde (MDA) serum concentration and insulin like growth factor-1 (IGF-1) relative level from brain tissue were determined. Results: Only the combined EGF+GHRP6 therapy reduced the clinical score in mild as well in severe EAE forms. The combination also improved the survival rate in nearly 100% of the severe EAE animals. In addition to these effects, there was an increase in the brain IGF-1 transcript and a decrease of serum MDA. Conclusions: EGF+GHRP6 proved to be effective in improving the natural course of both mild and severe EAE. Accordingly, the treatment reduces inflammatory infiltration and microvascular damage, which may be associated to the attenuation of the lipid peroxidation process and the transcriptional enhancement of IGF-1, a major pro-survival factor for brain cells.
Keywords: EAE, multiple sclerosis therapy, EGF, GHRP\(_{\rm{6}}\), IGF-1
DOI: 10.3233/RNN-2011-0595
Journal: Restorative Neurology and Neuroscience, vol. 29, no. 4, pp. 243-252, 2011
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]